Vertex Pharmaceuticals Inc (VRTX)
473.30
+2.18
(+0.46%)
USD |
NASDAQ |
Nov 04, 16:00
480.58
+7.28
(+1.54%)
Pre-Market: 08:32
Vertex Pharmaceuticals Cash from Investing (Quarterly): -463.70M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -463.70M |
| March 31, 2024 | -2.136B |
| December 31, 2023 | -886.50M |
| September 30, 2023 | -117.70M |
| June 30, 2023 | -303.90M |
| March 31, 2023 | -1.834B |
| December 31, 2022 | 175.60M |
| September 30, 2022 | -384.20M |
| June 30, 2022 | -61.50M |
| March 31, 2022 | -51.00M |
| December 31, 2021 | -134.00M |
| September 30, 2021 | -52.90M |
| June 30, 2021 | -79.70M |
| March 31, 2021 | -74.30M |
| December 31, 2020 | 243.76M |
| September 30, 2020 | -247.94M |
| June 30, 2020 | 71.91M |
| March 31, 2020 | 31.67M |
| December 31, 2019 | -896.97M |
| September 30, 2019 | -249.00M |
| June 30, 2019 | -50.19M |
| March 31, 2019 | -39.14M |
| December 31, 2018 | -40.90M |
| September 30, 2018 | -49.89M |
| June 30, 2018 | -116.30M |
| Date | Value |
|---|---|
| March 31, 2018 | 4.933M |
| December 31, 2017 | -20.79M |
| September 30, 2017 | -225.28M |
| June 30, 2017 | -76.28M |
| March 31, 2017 | -160.98M |
| December 31, 2016 | 176.94M |
| September 30, 2016 | 34.79M |
| June 30, 2016 | -57.78M |
| March 31, 2016 | -102.71M |
| December 31, 2015 | -122.69M |
| September 30, 2015 | -100.94M |
| June 30, 2015 | 278.44M |
| March 31, 2015 | 214.04M |
| December 31, 2014 | -18.01M |
| September 30, 2014 | 30.54M |
| June 30, 2014 | 89.88M |
| March 31, 2014 | -20.41M |
| December 31, 2013 | -119.81M |
| September 30, 2013 | 49.54M |
| June 30, 2013 | -4.691M |
| March 31, 2013 | -37.60M |
| December 31, 2012 | 7.156M |
| September 30, 2012 | -131.23M |
| June 30, 2012 | -70.04M |
| March 31, 2012 | -231.70M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-2.136B
Minimum
Mar 2024
243.76M
Maximum
Dec 2020
-379.02M
Average
-117.70M
Median
Sep 2023
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly and Co | -4.005B |
| Bristol-Myers Squibb Co | -219.00M |
| Regeneron Pharmaceuticals Inc | -574.40M |
| Sarepta Therapeutics Inc | -98.53M |
| Moderna Inc | 1.649B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.754B |
| Cash from Financing (Quarterly) | -358.60M |
| Free Cash Flow | -1.426B |
| Free Cash Flow Per Share (Quarterly) | -14.84 |
| Free Cash Flow to Equity (Quarterly) | -3.830B |
| Free Cash Flow to Firm (Quarterly) | -3.830B |
| Free Cash Flow Yield | -1.16% |